Headlines about Relypsa (NASDAQ:RLYP) have been trending somewhat positive on Sunday, according to Accern Sentiment. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Relypsa earned a media sentiment score of 0.03 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.7568709020084 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Relypsa, Inc is a United States-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of polymer-based medicines. The Company’s technology platform includes a high-throughput chemistry process, enabling the Company to explore various potential polymer medicines for each disease it seeks to address.
Receive News & Ratings for Relypsa Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relypsa Inc and related companies with MarketBeat.com's FREE daily email newsletter.